Clinical Trials
79
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (37 trials with phase data)• Click on a phase to view related trials
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 47
- Registration Number
- NCT07053345
- Locations
- 🇰🇷
Cha Ilsan Medical Center, Goyang Si Gyeonggi Do, Korea, Republic of
🇰🇷Wonkwang University Hospital, Iksan, Korea, Republic of
🇰🇷Kyung Hee University Medical Center, Seoul, Korea, Republic of
A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants
- Conditions
- Chronic Graft vs Host Disease
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 15
- Registration Number
- NCT04852692
- Locations
- 🇰🇷
The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Korea, Republic of
🇰🇷Soonchunhyang University Bucheon Hospital, Bucheon-Si, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
A Study of the Newly Formulated Tylenol Tablet (Acetaminophen) to the Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in Healthy Participants
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 30
- Registration Number
- NCT04230252
- Locations
- 🇰🇷
H plus Yangji Hospital, Seoul, Korea, Republic of
A Study of Newly Formulated Tylenol Tablet (Acetaminophen) and Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in Healthy Participants
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 30
- Registration Number
- NCT04214691
- Locations
- 🇰🇷
H plus Yangji Hospital, Seoul, Korea, Republic of
Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 685
- Registration Number
- NCT03942120
- Locations
- 🇰🇷
The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Korea, Republic of
🇰🇷Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Inje University Haeundae Paik Hospital, Busan, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 16
- Next